Triple versus dual antiplatelet therapy for coronary heart disease patients undergoing percutaneous coronary intervention: A meta-analysis

Experimental and Therapeutic Medicine

Volumn 6, Issue 4, 2013, Pages 1034-1040

  Zhou, Hong ^a   Feng, Xiao Ling ^a   Zhang, Hong Ying ^a   Xu, Fei Fei ^a   Zhu, Jie ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Antiplatelet therapy; Cilostazol; Coronary heart disease; Meta analysis; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; CILOSTAZOL;

ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; SENSITIVITY ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 84883217940     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1238     Document Type: Article

References (32)

1. Aradi D, Komócsi A, Price MJ, et al: Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. Int J Cardiol: Jun 15, 2012 (Epub ahead of print).
2. Meryon I, Patel N, Millane T and Varma C: Normal coronary angiography and primary percutaneous coronary intervention for ST elevation myocardial infarction: a literature review and audit findings. Int J Clin Pract 64: 1245-1251, 2010.
3. Mercado N and Serruys PW: A meta-analytical approach for the treatment of in-stent restenosis. Eur Heart J 24: 217-218, 2003.
4. Meier B, Bachmann D and Lüscher T: 25 years of coronary angioplasty: almost a fairy tale. Lancet 361: 527, 2003.
5. Mrdovic I, Savic L, Lasica R, et al: Usefulness of the RISK-PCI score to predict stent thrombosis in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a substudy of the RISK-PCI trial. Heart Vessels 28: 424-433, 2013.
6. Gurbel PA and Tantry US: Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19: 439-448, 2006.
7. Takahashi S, Kaneda H, Tanaka S, et al: Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 71: 226-228, 2007.
8. Suh JW, Lee SP, Park KW, et al: Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. J Am Coll Cardiol 57: 280-289, 2011.
9. Regensteiner JG and Stewart KJ: Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nat Clin Pract Cardiovasc Med 3: 604-610, 2006.
10. Jeong YH, Lee SW, Choi BR, et al: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 53: 1101-1109, 2009.
11. Tamhane U, Meier P, Chetcuti S, et al: Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 5: 384-393, 2009.
12. Lee SW, Park SW, Hong MK, et al: Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46: 1833-1837, 2005.
13. Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1558, 2002.
14. Zintzaras E and Ioannidis JP: Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 28: 123-137, 2005.
15. DerSimonian R and Kacker R: Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28: 105-114, 2007.
16. Mantel N and Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748, 1959.
17. Peters JL, Sutton AJ, Jones DR, Abrams KR and Rushton L: Comparison of two methods to detect publication bias in meta-analysis. JAMA 295: 676-680, 2006.
18. Ahn CM, Hong SJ, Park JH, Kim JS and Lim DS: Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 26: 502-510, 2011.
19. Chen YD, Lu YL, Jin ZN, Yuan F and Lu SZ: A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. Chin Med J (Engl) 119: 360-366, 2006.
20. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al: Coronary stent restenosis in patients treated with cilostazol. Circulation 112: 2826-2832, 2005.
21. Han Y, Li Y, Wang S, et al: Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 157: 733-739, 2009.
22. Kim JY, Lee K, Shin M, et al: Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention. Circ J 71: 1867-1872, 2007.
23. Lee SW, Chun KJ, Park SW, et al: Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). Am J Cardiol 105: 168-173, 2010.
24. Lee SW, Park SW, Kim YH, et al: A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. J Am Coll Cardiol 57: 1264-1270, 2011.
25. Lu YL, Chen YZ, Lv SZ, Pan WZ and Liu X: Cilostazol prevention in elderly coronary heart disease patients with coronary bare metal stent restenosis after effect. Chin J Geriatr 25: 537-538, 2006. (In Chinese).
26. Schleinitz MD, Olkin I and Heidenreich PA: Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J 148: 990-997, 2004.
27. Smith SC Jr., Dove JT, Jacobs AK, et al: ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 103: 3019-3041, 2001.
28. Singh I, Shafiq N, Pandhi P, et al: Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query. Br J Clin Pharmacol 68: 4-13, 2009.
29. Biondi-Zoccai GG, Lotrionte M, Anselmino M, et al: Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 155: 1081-1089, 2008.
30. Friedland SN, Eisenberg MJ and Shimony A: Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol 109: 1397-1404, 2012.
31. Hong SJ, Choi SC, Ahn CM, Park JH, Kim JS and Lim DS: Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients. Heart 97: 1425-1432, 2011.
32. Hashiguchi M, Ohno K, Nakazawa R, Kishino S, Mochizuki M and Shiga T: Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. Cardiovasc Drugs Ther 18: 211-217, 2004.